Skye Bioscience (SKYE) Interest & Investment Income (2012 - 2026)
Skye Bioscience (SKYE) posted quarterly Interest & Investment Income of $169615.0 for Q1 2026, down 72.6% year-over-year from $619054.0 in Q1 2025, and down 38.12% quarter-over-quarter from $274096.0 in Q4 2025.
Skye Bioscience (SKYE) Interest & Investment Income (2012 - 2026) Analysis & Trends
Skye Bioscience (SKYE) has reported Interest & Investment Income for 9 consecutive years, with $169615.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest & Investment Income fell 72.6% year-over-year to $169615.0; the TTM figure through Mar 2026 stood at $1.4 million (down 56.67% YoY), while the FY2025 annual figure was $1.9 million, down 37.8% from the prior year.
- Interest & Investment Income fell to $169615.0 in Q1 2026 per SKYE's latest filing, from $274096.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $961237.0 in Q2 2024 and bottomed at $8598.0 in Q2 2023.
- Historically, Interest & Investment Income has averaged $368720.1 across 5 years, with a median of $346285.0 in 2025.
- Annual changes were most pronounced in 2024 — Interest & Investment Income surged 11079.77% — and 2026, when it plunged 72.6%.
- Skye Bioscience's Interest & Investment Income stood at $19011.0 in 2022, then soared by 164.61% to $50305.0 in 2023, then jumped by 1355.67% to $732274.0 in 2024, then sank by 62.57% to $274096.0 in 2025, then plunged by 38.12% to $169615.0 in 2026.
- Business Quant data shows SKYE's Interest & Investment Income at $169615.0 in Q1 2026, $274096.0 in Q4 2025, and $418474.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Skye Bioscience | 10.86 Mn | 10.86 Mn | - | 103,208.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 169,615.00 |
| Dec 31, 2025 | 274,096.00 |
| Sep 30, 2025 | 418,474.00 |
| Jun 30, 2025 | 533,090.00 |
| Mar 31, 2025 | 619,054.00 |
| Dec 31, 2024 | 732,274.00 |
| Sep 30, 2024 | 907,697.00 |
| Jun 30, 2024 | 961,237.00 |
| Mar 31, 2024 | 427,554.00 |
| Dec 31, 2023 | 50,305.00 |
| Sep 30, 2023 | 16,562.00 |
| Jun 30, 2023 | 8,598.00 |
| Mar 31, 2023 | 24,514.00 |
| Dec 31, 2022 | 19,011.00 |
| Dec 31, 2018 | 10.00 |
| Jun 30, 2018 | 74.00 |
| Apr 30, 2014 | 632.00 |
| Oct 31, 2013 | 391.00 |
| Jul 31, 2013 | 94.00 |
| Apr 30, 2013 | 162.00 |